The DCUN1D4 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid line, featuring targeted disruption of the DCUN1D4 gene. This heterogeneous cell pool is designed for functional genomics studies, circumventing the limitations of clonal isolation while preserving genetic diversity relevant to neddylation and ubiquitin-proteasome research. The polyclonal format is particularly suited for assays where population-level responses are desirable.
Raji cells are a suspension B lymphoblastoid line originally isolated from an 11-year-old Nigerian male with Burkitt lymphoma. They harbor the characteristic MYC-IGH t(8;14) translocation and are latently infected with Epstein-Barr virus (EBV), rendering them a prototypical model for B-cell malignancies and viral oncogenesis. Raji cells are widely employed in immunology and cancer research to study B-cell signaling, apoptosis, and the molecular underpinnings of EBV-mediated transformation.
The DCUN1D4 gene product functions as a dedicated cofactor for the NEDD8 E2 enzyme UBE2M, promoting the transfer of NEDD8 to cullin proteins and thereby activating cullin-RING E3 ubiquitin ligases (CRLs). DCUN1D4 directly interacts with cullin family members CUL1?C5 and RBX1, facilitating the ubiquitination of substrates including p27, cyclin E, I??B??, ??-catenin, and HIF-1??. This positions DCUN1D4 at the intersection of cell cycle control, NF-??B and Wnt signaling, and DNA damage response pathways. Its expression is regulated by c-Myc and modulated by NF-??B and EBV oncoproteins, linking neddylation to critical lymphomagenic networks.
In Raji cells, DCUN1D4 disruption impairs cullin neddylation, leading to reduced CRL activity and stabilization of tumor-suppressive substrates. This is predicted to perturb cell cycle progression, enhance apoptosis, and dysregulate NF-??B transcriptional output, providing a model to study neddylation-dependent oncogenic mechanisms. The knockout pool also allows examination of how EBV latency products exploit host neddylation machinery, and as DCUN1D4 is overexpressed in B-cell lymphomas, it serves as a platform for preclinical validation of neddylation inhibitors.
Applications include neddylation inhibitor screening via viability or apoptosis assays, Western blot monitoring of cullin neddylation with anti-NEDD8 antibodies, and NF-??B reporter analysis. The polyclonal cells are compatible with flow cytometric cell cycle profiling, Annexin V/7-AAD apoptosis detection, and transcriptomic profiling by RNA-seq. This knockout pool is a valuable resource for target validation studies linking DCUN1D4 to lymphomagenesis and EBV-driven B-cell immortalization. For further information, contact Ascent Research.
